drugset / Trial / NCT04649242

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

NCT04649242

Phase 3 Recruiting 2100 enrolled Pfizer
RandomizedSequentialTriple-blindTreatment

Summary

The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in children and adolescents.

Timeline

Start
2021-01-15
Primary completion
2029-01-09
Completion
2029-01-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rimegepant Small molecule 50 mg
Comparator Rimegepant Small molecule 75 mg

Indications